The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Molleculin
Consulting or Advisory Role - deciphera; GlaxoSmithKline
Research Funding - ASCO (Inst); Deciphera (Inst); Gradalis (Inst); Novartis (Inst); Solaris Health (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - NCCN
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics; Viracta Therapeutics
Research Funding - AADi (Inst); Abbvie (Inst); Advaxis (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BioEclipse Therapeutics (Inst); BiolineRx (Inst); BiolineRx (Inst); BioNTech (Inst); BioXCel therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Codiak Biosciences (Inst); Coordination Therapeutics (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); Dracen (Inst); Driver Group (Inst); DynamiCure Biotechnology (Inst); Elevation Oncology (Inst); Endocyte (Inst); Faeth Therapeutics (Inst); FibroGen (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HCW Biologics (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); HiberCell (Inst); I-Mab (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); InhibRx (Inst); Inhibrx (Inst); Intra ImmuSG (Inst); Istari Oncology (Inst); Jubilant Therapeutics (Inst); Lilly/ImClone (Inst); MabVax (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoResponse (Inst); PEEL Therapeutics (Inst); Pfizer (Inst); Pionyr (Inst); Pionyr (Inst); Plexxikon (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Riboscience (Inst); Rubius Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Sirnaomics (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trishula Therapeutics (Inst); TTC Oncology (Inst); TTC Oncology (Inst); Vedanta Biosciences (Inst); Veru (Inst); Y-mAbs Therapeutics (Inst); Zai Lab (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Jonathan C. Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Sen Zhang
Employment - EMD Serono; Theseus Pharmaceuticals
Stock and Other Ownership Interests - Theseus Pharmaceuticals
Travel, Accommodations, Expenses - Theseus Pharmaceuticals
 
Narayana Narasimhan
Employment - Theseus Pharmaceuticals
Stock and Other Ownership Interests - Theseus Pharmaceuticals
 
Victor M. Rivera
Employment - Theseus Pharmaceuticals
Leadership - Theseus Pharmaceuticals
Stock and Other Ownership Interests - Theseus Pharmaceuticals
 
David Kerstein
Employment - Theseus Pharmaceuticals
Stock and Other Ownership Interests - Theseus Pharmaceuticals
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)